{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:08Z","timestamp":1786988048287,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:00:00Z","timestamp":1694908800000},"content-version":"vor","delay-in-days":78,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejim.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T08:55:37Z","timestamp":1681289737000},"page":"10-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Xanthine oxidase inhibition and cardiovascular protection: Don't shoot in the dark"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-1271","authenticated-orcid":false,"given":"Giovambattista","family":"Desideri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejim.2023.04.006_bib0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2023.04.006_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.006_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2047487313514895","article-title":"Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis","volume":"22","author":"Clarson","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.ejim.2023.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","article-title":"Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout","volume":"4","author":"Klauser","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2023.04.006_bib0005","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1093\/rheumatology\/keab335","article-title":"The inflammatory role of silent urate crystal deposition in intercritical gout","volume":"60","author":"Diaz-Torne","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.006_bib0006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"from the working group on uric acid and cardiovascular risk of the italian society of hypertension. identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.04.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102195","article-title":"Xanthine oxidoreductase: a leading actor in cardiovascular disease drama","volume":"48","author":"Polito","year":"2021","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.006_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/HJH.0000000000002287","article-title":"Working group on uric acid and cardiovascular risk of the italian society of hypertension (siia). serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: the urrah (uric acid right for heart health) study","volume":"38","author":"Casiglia","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.04.006_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2016.11.077","article-title":"Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure","volume":"228","author":"Otaki","year":"2017","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.006_bib0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Bredemeier","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"issue":"20","key":"10.1016\/j.ejim.2023.04.006_bib0011","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"NHLBI heart failure clinical research network. effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.04.006_bib0012","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.04.006_bib0013","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ejim.2023.04.006_bib0014","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and cardiorenovascular events prevention stuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"issue":"10359","key":"10.1016\/j.ejim.2023.04.006_bib0015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"ALL-HEART study group. allopurinol versus usual care in uk patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:39:27Z","timestamp":1760607567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523001176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"alternative-id":["S0953620523001176"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.04.006","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Xanthine oxidase inhibition and cardiovascular protection: Don't shoot in the dark","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}